vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Sunrun Inc. (RUN). Click either name above to swap in a different company.

Sunrun Inc. is the larger business by last-quarter revenue ($1.2B vs $749.2M, roughly 1.5× CLOVER HEALTH INVESTMENTS, CORP.). Sunrun Inc. runs the higher net margin — 8.9% vs 3.6%, a 5.3% gap on every dollar of revenue. On growth, Sunrun Inc. posted the faster year-over-year revenue change (123.5% vs 62.0%). Over the past eight quarters, Sunrun Inc.'s revenue compounded faster (59.0% CAGR vs 45.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Sunrun Inc. is an American provider of photovoltaic systems and battery energy storage products, primarily for residential customers. The company was established in 2007 and is headquartered in San Francisco, California.

CLOV vs RUN — Head-to-Head

Bigger by revenue
RUN
RUN
1.5× larger
RUN
$1.2B
$749.2M
CLOV
Growing faster (revenue YoY)
RUN
RUN
+61.5% gap
RUN
123.5%
62.0%
CLOV
Higher net margin
RUN
RUN
5.3% more per $
RUN
8.9%
3.6%
CLOV
Faster 2-yr revenue CAGR
RUN
RUN
Annualised
RUN
59.0%
45.0%
CLOV

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
RUN
RUN
Revenue
$749.2M
$1.2B
Net Profit
$27.3M
$103.6M
Gross Margin
Operating Margin
3.6%
8.4%
Net Margin
3.6%
8.9%
Revenue YoY
62.0%
123.5%
Net Profit YoY
103.7%
EPS (diluted)
$0.05
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
RUN
RUN
Q1 26
$749.2M
Q4 25
$487.7M
$1.2B
Q3 25
$496.6M
$724.6M
Q2 25
$477.6M
$569.3M
Q1 25
$462.3M
$504.3M
Q4 24
$337.0M
$518.5M
Q3 24
$331.0M
$537.2M
Q2 24
$356.3M
$523.9M
Net Profit
CLOV
CLOV
RUN
RUN
Q1 26
$27.3M
Q4 25
$-49.3M
$103.6M
Q3 25
$-24.4M
$16.6M
Q2 25
$-10.6M
$279.8M
Q1 25
$-1.3M
$50.0M
Q4 24
$-22.1M
$-2.8B
Q3 24
$-9.2M
$-83.8M
Q2 24
$7.4M
$139.1M
Gross Margin
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
RUN
RUN
Q1 26
3.6%
Q4 25
-10.1%
8.4%
Q3 25
-4.9%
0.5%
Q2 25
-2.2%
-19.7%
Q1 25
-0.3%
-22.8%
Q4 24
-6.4%
-628.0%
Q3 24
-2.7%
-23.8%
Q2 24
2.0%
-24.4%
Net Margin
CLOV
CLOV
RUN
RUN
Q1 26
3.6%
Q4 25
-10.1%
8.9%
Q3 25
-4.9%
2.3%
Q2 25
-2.2%
49.1%
Q1 25
-0.3%
9.9%
Q4 24
-6.6%
-542.7%
Q3 24
-2.8%
-15.6%
Q2 24
2.1%
26.5%
EPS (diluted)
CLOV
CLOV
RUN
RUN
Q1 26
$0.05
Q4 25
$0.38
Q3 25
$0.06
Q2 25
$1.07
Q1 25
$0.20
Q4 24
$-12.59
Q3 24
$-0.37
Q2 24
$0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
RUN
RUN
Cash + ST InvestmentsLiquidity on hand
$177.6M
Total DebtLower is stronger
$14.7B
Stockholders' EquityBook value
$339.4M
$3.1B
Total Assets
$697.7M
$22.6B
Debt / EquityLower = less leverage
4.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
RUN
RUN
Q1 26
$177.6M
Q4 25
$78.3M
Q3 25
Q2 25
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Total Debt
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
$14.7B
Q3 25
$14.6B
Q2 25
$14.0B
Q1 25
$13.6B
Q4 24
$12.9B
Q3 24
$12.5B
Q2 24
$12.0B
Stockholders' Equity
CLOV
CLOV
RUN
RUN
Q1 26
$339.4M
Q4 25
$308.7M
$3.1B
Q3 25
$340.9M
$3.0B
Q2 25
$344.2M
$2.9B
Q1 25
$336.1M
$2.6B
Q4 24
$341.1M
$2.6B
Q3 24
$342.2M
$5.3B
Q2 24
$324.9M
$5.4B
Total Assets
CLOV
CLOV
RUN
RUN
Q1 26
$697.7M
Q4 25
$541.0M
$22.6B
Q3 25
$559.7M
$22.2B
Q2 25
$575.0M
$21.2B
Q1 25
$583.7M
$20.4B
Q4 24
$580.7M
$19.9B
Q3 24
$653.0M
$22.1B
Q2 24
$674.2M
$21.4B
Debt / Equity
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
4.69×
Q3 25
4.90×
Q2 25
4.80×
Q1 25
5.19×
Q4 24
5.05×
Q3 24
2.36×
Q2 24
2.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
RUN
RUN
Operating Cash FlowLast quarter
$96.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.94×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
$-66.9M
$96.9M
Q3 25
$12.1M
$-121.5M
Q2 25
$5.4M
$-292.7M
Q1 25
$-16.3M
$-104.2M
Q4 24
$34.8M
$-258.4M
Q3 24
$50.0M
$-156.2M
Q2 24
$44.8M
$-208.5M
Free Cash Flow
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
$-156.4M
Q2 24
$44.4M
FCF Margin
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
-29.1%
Q2 24
12.5%
Capex Intensity
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
0.0%
Q2 24
0.1%
Cash Conversion
CLOV
CLOV
RUN
RUN
Q1 26
Q4 25
0.94×
Q3 25
-7.33×
Q2 25
-1.05×
Q1 25
-2.08×
Q4 24
Q3 24
Q2 24
6.04×
-1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

RUN
RUN

Products$692.3M60%
Customer Agreements$435.2M38%
Manufactured Product Other$56.7M5%
Incentives$31.3M3%

Related Comparisons